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Background: Endothelial nitric oxide synthase (eNOS) gene polymorphisms have been associated with
the pathogenesis of cardiovascular diseases, but few studies have evaluated the role of eNOS haplotypes
on the risk and prognosis of heart failure (HF). This prospective study was designed to analyze the impact
of three eNOS polymorphisms (T-786C, VNTR4a/b and Glu298Asp) and their haplotypes on the suscepti-
bility and clinical outcomes in HF outpatients with systolic dysfunction.
Methods and results: We conducted a case-control and a cohort study in which 316 HF patients and 360
healthy controls were recruited from a tertiary care university hospital. DNA was extracted from periph-
eral blood and eNOS polymorphisms were detected by PCR or PCR-RFLP. Patients were predominantly
men, had a mean left ventricular ejection fraction of 31% and were followed-up for a median of
41 months; there were 96 deaths, including 58 HF-related deaths. Genotype distribution of the eNOS
T-786C, VNTR 4a/b and Glu298Asp was similar between HF patients and controls. Haplotype frequencies
differed between HF patients and controls only in African–Brazilians (p = 0.043). African–Brazilian
patients that carried the haplotype -786C/4b/Asp298 had a better prognosis than patients that carried
other haplotypes (log rank p value = 0.016 for all-cause mortality). In a Cox proportional hazard model
adjusted for clinical variables of risk, the -786C/4b/Asp298 haplotype remained as an independent
genetic predictor of survival (adjusted HR = 0.11; 95% CI = 0.01–0.83; p = 0.03).
Conclusions: The -786C/4b/Asp298 eNOS haplotype had a signiﬁcant impact on HF susceptibility and
prognosis, particularly in African–Brazilian patients.
 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Basic and clinical evidence suggests that defects in nitric oxide
(NO) generation and action are involved in the pathogenesis of
several cardiovascular syndromes [1–3]. Physiological levels of
NO appear to play an important protective role in heart failure
(HF), but higher levels have also been associated to detrimental
negative inotropic effects on the heart [4]. Endothelial NO synthase
(eNOS) is the predominant source of vascular NO and its synthesis
is constitutively mediated by a reaction that involves the conver-
sion of L-arginine to L-citruline [5]. Variation in NO availability,
an alleged risk for cardiovascular disease, could be explained in
part by eNOS genetic polymorphisms that modify protein
expression and/or activity [6–7].Transplant Unit, Cardiology
iro Barcelos 2350, Sala 2061,
8344.
ical Sciences of the Lutheran
evier OA license.The eNOS protein is encoded by the NOS3 gene, located on the
chromosome 7q35-36 and is comprised of 26 exons [8]. A single
nucleotide variation occurs on the promoter region of the eNOS
gene (a T-to-C transition [T-786C], rs2070744). The -786C allele
was associated with reduced eNOS activity in human platelets
[9] and reduced mRNA levels in human cardiomyocytes [10]. The
-786C variant was also linked to the risk of coronary artery disease
and hypertension [1,3]. Another common eNOS polymorphism
involves an amino acid substitution in exon 7 of the mature protein
(a G-to-T transversion [G894T], rs1799983), leading to a gluta-
mate-aspartate substitution at codon 298 (Glu298Asp). The
Asp298 variant was reported to be a main risk factor for ischemic
heart disease [11] and was associated with worse event-free
survival in non-ischemic HF patients [2]. Finally, a 27-bp repeat
in intron 4 (VNTR intron 4a/b) has been associated to physiologic
variations of the plasmatic concentrations of NO metabolites
[12]. This variant has also been linked to the severity of coronary
stenosis [13] and the risk of myocardial infarction in the Tunisian
population [14].
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single nucleotide polymorphisms (SNPs), as those mentioned
above, have been criticized because results are rarely reproducible
across populations with different genetic backgrounds. In this
scenario, it is well recognized that the expression and/or activity
of proteins frequently vary according to haplotype clusters. Haplo-
type analysis might overcome some of the inconsistencies
observed in studies that evaluated individual SNPs, providing
enhanced predictive power and reproducibility in association stud-
ies [15]. Recently, several reports have pointed out that eNOS
haplotypes might substantially interfere with NO formation, as
well as with levels of plasma and whole blood nitrite [12–16]. In
the present study we evaluated the role of the T-786C, VNTR 4a/
b and Glu298Asp eNOS gene polymorphisms, individually and by
haplotypes, as markers of disease susceptibility and prognosis in
a South-Brazilian cohort of HF patients.Methods
Subjects
Heart failure patients were recruited from a tertiary care uni-
versity hospital in Porto Alegre, Brazil. Consecutive eligible
patients who agreed to participate were enrolled at the Heart
Failure and Transplant Outpatient Clinic between October, 2003
and October, 2007. A total of 316 patients with systolic HF (222
Caucasians and 94 African–Brazilians) were enrolled in the study.
Inclusion criteria were age >18 years and left ventricular ejection
fraction (LVEF) < 45%. Patients with other serious illnesses or with
reduced life expectancies were excluded. The ethnical classiﬁca-
tion of all participants was self-reported. Demographic, clinical,
and routine laboratory data from all patients were collected using
a structured data form. We also evaluated 360 healthy blood
donors from the blood bank center of the same hospital. Before
blood donation, volunteers who chose to participate of the study
underwent a systematic interview. Subjects who reported a posi-
tive family history of premature sudden death or cardiovascular
diseases (in ﬁrst degree relatives, irrespective of age), the presence
of atherosclerotic risk factors, or any overt clinical disease were
excluded from the protocol. However, no additional laboratory
data was collected from blood donors. The study protocol was
approved by the local institutional review board and by the
National Agency of Ethics in Research and all subjects provided
written informed consent.Genotyping
Genomic DNA was extracted from samples of peripheral blood
using a commercially available kit (Puregene; Gentra Systems,
Minneapolis, USA). Gene fragments containing the T-786C and
the G894T (Glu298Asp) variant sites in eNOS gene were ampliﬁed
by polymerase chain reaction (PCR), using experimental conditions
as previously described [17]. Ampliﬁcation products were digested
with the appropriate restriction enzymes under the conditions
recommended by the manufacturer (MBI Fermentas, St. Leon-
Rot., Germany). The digested fragments were then separated by
electrophoresis on 6% polyacrylamide gels, followed by ethidium
bromide staining, and directly visualized under ultraviolet light.
The VNTR polymorphism in intron 4 was detected by PCR using
primers and conditions as previously described [18] and the alleles
were identiﬁed according to the length of bands after separation of
PCR fragments on ethidium bromide-stained 2% agarose gels. The
presence of four, ﬁve or six 27-bp repeats in intron 4 results in
amplicons of 393 bp (a allele), 420 bp (b allele) or 447 bp (c allele),
respectively.Outcome evaluation
Enrolled patients were followed-up at the Heart Failure and
Transplant Outpatient Clinic at our institution between October/
2003 through October/2007. At the HF clinic, patients were sched-
uled to have regular visits, with pre-deﬁned intervals from 1 to
4 months. Follow-up data was directly derived from reviewing all
electronic clinical data from the institution’s records (most
patients had several follow-up visits). For patients that were not
regularly visiting the HF clinic (or had lost the follow-up), a
telephone contact was attempted to check for relevant clinical
events, based on a structured telephone interview performed by
trained nurses. For those who we were unable to be contacted by
phone (approximately 20 patients), we checked their vital status
through the State Death Certiﬁcate Database (that contains data
about the main cause and date of all death in our state). Analyses
were stratiﬁed by the presumptive cause of death, classiﬁed as
(1) all-cause mortality and (2) HF-related, deﬁned as sudden,
unexpected death (within 1 h of initiation of symptoms) or caused
by advanced refractory disease (pump failure).Statistical analysis
Continuous data are expressed as mean ± standard deviation or
median (interquartile ranges) and categorical variables are ex-
pressed as absolute numbers and percentages. Comparisons be-
tween groups were tested by the chi-square (v2), Student’s t test,
analysis of variance, or nonparametric statistics, as appropriate.
Allele frequencies were determined by gene counting and devia-
tions from the Hardy–Weinberg equilibrium were veriﬁed using
the v2 test. The v2 test was also used to evaluate the allele and
genotype distributions among groups of subjects and the residual
analysis was used to identify the categories responsible for statisti-
cal differences. The linkage disequilibrium between all pair of loci
was calculated and expressed in terms of r2 and D0 [19]. Haplotype
frequencies were estimated by a Bayesian method using the soft-
ware PHASE version 2.1 [20–21]. We also used PHASE program to
compare the distribution of different eNOS haplotypes between
HF patients and controls through permutation analyses of 1000
random replicates. Kaplan–Meier survival curves were constructed
from the date of entry at the outpatient clinic until the last registry
of follow-up or death, and compared by the log–rank statistics. Sur-
vival analysis for all patients (Fig. 1) was adjusted for self-reported
race. Cox proportional hazardmodels were created and adjusted for
age, gender, LVEF, serum sodium levels, duration of QRS, left
ventricular diastolic diameter (LVDD), acute myocardial infarction,
functional class (NYHA) and use of beta-blocker. A two-tailed p
value <0.05 was considered statistically signiﬁcant. Statistical anal-
yses were performed using SPSS version 18 for Windows.Results
Clinical characteristics
The clinical and demographic characteristics of HF patients are
presented according to self-reported ethnicity (Table 1). Both
groups, Caucasians and African–Brazilians, were mainly males
(67% and 73%), with mean age of 60 ± 13 and 59 ± 12 years, respec-
tively. African–Brazilian HF patients had a higher prevalence of
hypertensive etiology (34%) while Caucasians were predominantly
of ischemic etiology (42%). Most HF patients in both groups had
moderate to severe left ventricular dysfunction and were in New
York Heart Association (NYHA) class I or II. Patients were taking
standard background therapy for HF including angiotensin-
converting enzyme (ACE) inhibitors and beta-blockers. Healthy
Fig. 1. Kaplan–Meier survival curves comparing all HF patients between eNOS polymorphisms and haplotypes (A – T-786C; B – Glu298Asp; C – VNTR 4a/b; D – eNOS
haplotype).
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casian (77%), and their mean age was 45 ± 12 years (p = 0.001 vs.
HF patients).Genotype distribution in HF patients and controls
The genotype frequencies were in agreement with those pre-
dicted by the Hardy–Weinberg equilibrium for all eNOS polymor-
phisms in HF patients and controls. Supplementary Figures 1–3
illustrate the distribution of eNOS genotypes in HF patients and
controls, stratiﬁed by self-reported race. Genotype frequencies
for the three analyzed polymorphisms were similar between HF
patients and controls in both Caucasians and African–Brazilians
(Figure S1–S3). Regarding allele frequencies, we observed a small
difference for the eNOS T-786C that was restricted to African–
Brazilians (the C allele was more frequent in controls than in HF
patients; 0.31 vs. 0.21, respectively, p = 0.048). There were no dif-
ferences in allele frequencies for Glu298Asp and the VNTR intron
4a/b variants between African–Brazilian or Caucasians HF patients
and controls (data not shown).Linkage disequilibrium and haplotype analysis
Table S1 describes the linkage disequilibrium (LD) analysis
among eNOS polymorphisms, stratiﬁed by cases and controls,
and self-reported race. Most polymorphisms were not in LD, as
indicated by r2, but the T-786C polymorphism was weakly linked
with the VNTR intron 4 variant and the Glu298Asp polymorphism
in Caucasian HF patients. Among African–Brazilian HF patients, the
Glu298Asp and T-786C polymorphisms were also in weak LD.
We next analyzed if haplotype clusters would be associated
with HF using a Bayesian method to estimate the haplotype
frequencies composed by the three studied eNOS polymorphisms.
As the c allele of VNTR polymorphism in intron 4 was infrequent,
carriers of the c allele were excluded from haplotype analysis
and the VNTR intron 4 a/b polymorphism was considered a bi-alle-
lic marker. The most frequent haplotype in patients and controls
was -786T/4b/Glu298, both in Caucasians and African–Brazilians.
The haplotypes -786C/4a/Asp298 and -786T/4a/Asp298 were not
observed in African–Brazilians patients or in controls. In the Cauca-
sian group, we also did not ﬁnd the -786T/4a/Asp298 haplotype in
HF cases and controls.
Table 1
Clinical characteristics of HF patients according to ethnicity.
Characteristics Caucasians
N = 222
African–Brazilians
N = 94
p
Age (years) 60 ± 13 59 ± 12 0.45
Males 149 (67) 69 (73) 0.33
HF etiology
Ischemic 93 (42) 25 (27) 0.02
Hypertensive 43 (19) 32 (34) 0.01
Idiopathic 69 (31) 23 (24) 0.29
Chagas disease 4 (2) 5 (5) 0.17
Functional class
I and II 174 (81) 68 (73) 0.19
III and IV 42 (19) 25 (27)
Comorbidities
Myocardial infarction 81 (36) 20 (21) 0.01
Hypertension 122 (55) 64 (68) 0.04
Cerebrovascular disease 16 (7) 10 (11) 0.42
Diabetes mellitus 74 (33) 21 (22) 0.07
Current smoking 21 (9) 17 (18) 0.05
Echocardiography
LV ejection fraction (%) 31 ± 8 31 ± 8 0.84
LV diastolic diameter
(cm)
6.6 ± 1.0 6.6 ± 0.8 0.66
LA dimension (cm) 4.7 ± 0.8 4.8 ± 0.9 0.86
PASP (mmHg) 49 ± 13 49 ± 14 0.94
Electrocardiogram
Atrial ﬁbrillation 40 (18) 17 (18) >0.99
Left bundle branch
block
65 (29) 27 (29) >0.99
QRS duration (ms) 130 ± 34 128 ± 33 0.82
Laboratory variables
Creatinine (mg/dL) 1.3 ± 0.5 1.3 ± 0.5 0.52
Urea (mg/dL) 58.5 ± 31.0 54.0 ± 27.5 0.27
Sodium (mEq/L) 140.6 ± 3.2 140.0 ± 3.4 0.20
Potassium (mEq/L) 4.5 ± 0.6 4.4 ± 0.5 0.46
Hemoglobin (g/dL) 13.1 ± 1.6 12.9 ± 1.9 0.32
Initial drugs
Beta-blockers 197 (89) 80 (85) 0.47
ACEi 191 (86) 86 (91) 0.24
Spironolactone 91 (41) 30 (32) 0.17
Hidralazine 38 (17) 23 (24) 0.05
Isosorbide 50 (23) 25 (27) 0.09
Data are presented as means ± standard deviations or absolute numbers
(percentages).
HF, heart failure; LV, left ventricle; LA, left atrium; PASP, pulmonary artery systolic
pressure; ACEi, angiotensin-converting enzyme inhibitor.
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remarkably similar to those of apparently healthy blood donorsTable 2
Haplotype frequencies of eNOS polymorphisms in African–Brazilian and Caucasian patien
Haplotype* African–Brazilians
Controls, n (%) HF c
Number of chromosomes 160 180
-786T/4b/Glu298 86 (53.5) 111
-786T/4b/Asp298 12 (7.5) 13 (7
-786T/4a/Glu298 10 (6.5) 15 (8
-786C/4b/Glu298 13 (7.8) 6 (3.
-786C/4b/Asp298 32 (20.2) 21 (1
-786C/4a/Glu298 7 (4.5) 14 (7
-786C/4a/Asp298 – –
PHASE program version 2.1 was used for estimating haplotype frequencies and for com
* As the c allele (intron 4 VNTR) was very rare, carriers of this allele were excluded from
bi-allelic marker.
 P = 0.51 for Caucasian patients vs. controls.
 P = 0.043 for African–Brazilian patients vs. controls.
# Represents haplotype which contributes signiﬁcantly to v2 test, as indicated by residu(p > 0.05; Table 2). However, for the African–Brazilians, haplotype
frequencies were different between HF patients and controls; this
difference was mainly due to the -786C/4b/Asp298 haplotype
(p = 0.043; Table 2). We found a protective effect of this haplotype
on HF susceptibility (OR = 0.41; 95% CI = 0.21–0.82; p = 0.011), but
this protection was partially lost when adjusted for gender and age
(adjusted OR = 0.46; 95% CI = 0.21–1.01; p = 0.053).
Event-free survival
Patients with HF were followed-up for a median of 41 months.
During the follow-up there were 96 events, including 58 HF-
related deaths. We have evaluated the impact of eNOS promoter,
exon 7 and intron 4 polymorphisms and did not ﬁnd any effect
of these polymorphisms on survival for all patients (Fig. 1 A, B
and C, respectively). In addition, there was no signiﬁcant effect of
all three eNOS polymorphisms on survival in the analysis restricted
to Caucasian patients (data not shown). However, the presence of
the Glu298 variant was associated with a worse survival when
compared to Asp298 carriers in African–Brazilian patients
(p = 0.034; Fig. 2A). In a Cox regression analysis adjusted for LVEF,
age, gender, sodium levels and use of beta-blockers, the Glu298
variant did not remain as an independent predictor for all-cause
mortality (adjusted HR = 2.77; 95% CI = 0.93–8.19, p = 0.066;
Asp298 carriers as the reference group).
We further analyzed clinical outcomes in HF patients in relation
to the presence of one copy of the -786C/4b/Asp298 haplotype. We
did not ﬁnd any association of this haplotype with all-cause
mortality or HF-related death in analysis involving all patients
(Fig. 1D), and neither for analysis restricted to the Caucasian group
(data not shown). However, African–Brazilians carrying the -786C/
4b/Asp298 haplotype had a better prognosis when compared to
patients that carry other haplotypes (p = 0.016 Fig. 2B). After Cox
regression analysis adjusted for several other clinical predictors
of risk (Table 3), the 786C/4b/Asp298 haplotype persisted as inde-
pendent genetic predictor of survival (adjusted HR = 0.11; 95%
CI = 0.01–0.83; p = 0.03).
Discussion
Haplotype analysis has arisen as a more informative approach
to appraise the genetic inﬂuence on diseases rather than testing
isolated genetic markers. In the present study, haplotype analysis
of eNOS polymorphisms had a signiﬁcant impact on HF prognosis
in self-reported African–Brazilian patients. However, we failed to
demonstrate an association between isolated eNOS polymor-
phisms and HF susceptibility or clinical outcomes. This ﬁndingts and controls.
Caucasians
ases, n (%) Controls, n (%) HF cases, n (%)
560 440
(61.4) 241 (43.2) 207 (47.1)
.5) 67 (11.9) 53 (12)
.4) 22 (3.9) 15 (3.4)
4) 32 (5.8) 25 (5.6)
1.6)# 124 (22.1) 92 (21.0)
.7) 72 (12.8) 44 (10.1)
2 (0.3) 4 (0.8)
paring cases and controls.
haplotype analysis and the VNTR intron 4 a/b polymorphism was considered as a
al analysis.
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related to racial phenotype, a ﬁnding that has been suggested by
other investigators [2,17].
The effect of eNOS polymorphisms on susceptibility to cardio-
vascular disease has been previously evaluated in several scenar-
ios. Despite the fact that eNOS polymorphisms are linked to
eNOS activity [6,7] and thus can be expected to inﬂuence blood
pressure control, no association was found between these poly-
morphisms and the presence of hypertension in both Caucasian
and African–Brazilian patients [22]. A meta-analysis evaluating
the association between three eNOS polymorphisms and ischemic
heart diseases showed that there is a slightly increased risk associ-
ated with the presence of Asp298 and intron 4a alleles (OR = 1.17
and OR = 1.34, respectively), whereas no association was found be-
tween -786C allele and ischemic heart disease. It is noteworthy
that ethnic background was not a source of inter-study heteroge-
neity in this meta-analysis [11]. Velloso et al. have demonstrated
an increased prevalence of the Glu298Glu genotype and Glu298 al-
lele in patients with chronic HF [23]. On the other hand, a Canadian
study that has evaluated several polymorphisms in patients maxi-
mally treated for HF, including T-786C and Glu298Asp, has failed to
demonstrate any association of these polymorphisms with the dis-
ease [24]. Similar to these reports, we failed to demonstrate any
major association between three eNOS polymorphisms and HF
susceptibility. Studies in hypertensive patients, however, have
suggested that ethnic diversity and haplotype analysis could
contribute signiﬁcantly to hypertension susceptibility. Sandrim
et al. have demonstrated that even in the absence of association
between isolated eNOS polymorphisms and hypertension, one
haplotype (-786C/4b/Asp298) was more frequent in hypertensive
patients [22]. These ﬁndings were partially reproduced by our data,
as we observed a signiﬁcant effect of the -786C/4b/Asp298 haplo-
type on HF susceptibility in African–Brazilians.
Few studies have previously evaluated the role of eNOS gene
variants on HF prognosis. For instance, McNamara et al. have dem-
onstrated that Asp298 allele was associated with a poorer survival
in predominantly white (approximately 90%) non-ischemic HF
patients [2]. We failed to reproduce the detrimental effect of the
Asp298 variant in our mixed sample (Fig. 1A); on the contrary,Fig. 2. Kaplan–Meier survival curves comparing African–Brazilian patients who are As
haplotype).we observed that African–Brazilian HF patients carrying the
Asp298 allele had lower all-cause mortality (Fig. 2A) in univariate
analysis. This association was partially lost after adjustment for
other predictors of risk. Also, eNOS genotype inﬂuences blood pres-
sure and left ventricular remodeling but the polymorphisms
T-786C, Asp298Glu, and VNTR intron 4 had no impact on event-
free survival in African–American HF patients [25]. Thus, clinical
evidences suggest that several eNOS polymorphisms might have
differential effects according to race [2,17,25]. In addition,
Asp298 carrier condition was not associated with change in either
eNOS mRNA or protein expression in myocardial tissue obtained
from patients with advanced end-stage HF [10], indicating that
the associated changes in eNOS expression might be dependent
on the temporal stages of HF.
We have demonstrated that African–Brazilian HF patients who
carried the -786C/4b/Asp298 haplotype had a better long-term
prognosis. This protective effect remained statistically signiﬁcant
after adjustment for other known clinical variables of risk in a
Cox regression analysis. Although both -786C and Asp298 alleles
have been associated with several cardiovascular disease states
[3,23], their impact on HF progression could be dependent on dis-
tinct biological processes. As eNOS is expressed in several cell
types, not just in the endothelium, these differential effects are bio-
logically plausible.
It is well recognized that reactive oxygen species (ROS) may
induce oxidation and damage of macromolecules, membranes,
and DNA and thus detrimental for cellular function and viability.
In HF patients, the production of ROS is increased and the NO
system is disrupted leading to the interruption of signaling path-
ways and homeostatic mechanisms. One of the major controver-
sies surrounding NO in the heart is derived from the observation
that in HF and in cardiac injury due to myocardial infarction,
NOS isoforms have been ascribed both protective and detrimental
roles [26]. Some studies have shown that endothelial overexpres-
sion of eNOS attenuates LV dysfunction in mice after myocardial
infarction suggesting that NO was beneﬁcial in HF [27]. However,
this effect might be lost when eNOS uncoupling occurs in the pres-
ence of ROS, stimulating cardiac pathologic remodeling from
chronic pressure overload. One proposed mechanism of cardiacp298 carriers and -786C/4b/Asp298 haplotype carriers (A – Glu298Asp; B – eNOS
Table 3
Univariate analysis and Cox proportional hazard models for all-cause mortality in African–Brazilian patients.
Clinical characteristics Univariate analysis Adjusted model 1* Adjusted model 2*
HR 95% CI p HR 95% CI p HR 95% CI p
Sodium, each 1 mEq/L 0.80 0.71–0.90 0.023 0.77 0.67–0.89 <0.001 0.77 0.67–0.89 <0.001
QRS duration, each 10 ms 1.16 1.05–1.28 0.003 1.17 1.05–1.29 0.005 1.17 1.05–1.29 0.005
Beta-blocker 0.36 0.16–0.81 0.014 0.19 0.08–0.49 0.001 0.19 0.08–0.49 0.001
LVEF, each 1% 0.95 0.91–1.00 0.032 0.97 0.92–1.02 0.25 0.97 0.92–1.78 0.18
Haplotype -786C/4b/Asp298 0.13 0.02–0.93 0.042 0.11 0.01–0.83 0.03 0.11 0.01–0.83 0.03
LVDD, each 1 mm 1.35 0.89–2.03 0.156 0.91 0.51–1.64 0.76 1.11 0.70–1.78 0.65
AMI 1.96 0.92–4.19 0.083 2.37 1.08–5.21 0.03 2.37 1.08–5.21 0.03
NYHA Class III or IV 1.84 0.86–3.97 0.12 0.82 0.33–2.01 0.66 0.84 0.33–2.09 0.70
Age, each year 1.00 0.97–1.04 0.84 0.99 0.96–1.03 0.66 – – –
Sex (female as reference) 0.63 0.26–1.54 0.31 0.47 0.18–1.27 0.14 – – –
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; LVDD, left ventricular diastolic diameter; AMI, acute myocardial infarction.
* Model 1 was adjusted for all variables. Model 2 was not adjusted for age and sex.
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production of NO in the heart, particularly in cardiac myocytes. It
has been demonstrated that NO donors increase cardiomyocyte
cell death and switch cell death form from apoptosis to necrosis
in a concentration dependent manner [28]. The detrimental effect
of excess NO is attributed to its action on the mitochondria, by
inhibiting the mitochondrial respiratory chain, resulting in in-
creased oxidant production and increased susceptibility to cell
death [29]. Moreover, elevated levels of circulating cytokines could
stimulate the expression of inducible NOS, with consequent over-
production of NO which has been shown to have negative inotropic
effects on failing hearts that have undergone b-adrenergic stimula-
tion [30]. Taking into account that -786C and Asp298 alleles are
related to low levels of mRNA and enzyme activity [6,7,9,10], the
above data could explain, in part, how the -786C/4b/Asp298 haplo-
type might have a protective role in HF.
We must consider some methodological aspects of our study.
First, our African–Brazilian patients and controls could be consid-
ered a mixed population and this could be a confounding variable.
Second, previous studies that analyzed eNOS haplotypes were car-
ried out in patients with heterogeneous disease states, such as cor-
onary artery disease and hypertension [1,22]. These entities have
distinct phenotypes and different progression proﬁles and thus
should be cautiously compared to HF cohorts. Also, our results
are derived from a relatively small sized cohort of HF patients,
based on the analysis of speciﬁc pre-deﬁned polymorphism (and
not genome-wide analysis); as such our ﬁndings must be inter-
preted with caution and be considered hypothesis generators. In
addition, because our sample size we were underpowered to
perform an interaction analysis of ethnicity and clinical outcomes.
Finally, the VNTR intron 4 polymorphisms typically would not be
suitable for haplotype analysis. However, as the c allele was very
rare, carriers of this allele were excluded from haplotype analysis
and the VNTR intron 4 a/b polymorphism was considered as a
bi-allelic marker. This approach has been consistently used ‘‘suc-
cessfully’’ by several groups of investigators [31,32].
In conclusion, we showed that the -786C/4b/Asp298 haplotype
had a protective effect on HF susceptibility among African–
Brazilian subjects, as well as an important beneﬁcial impact on
HF outcome in African–Brazilian patients. On the other hand, the
distribution of individual eNOS polymorphisms had no major
differences between HF patients and controls in both Caucasians
and African–Brazilians. Haplotype analyses may help to underscore
the ﬁnal effects of genetically determined eNOS variability in HF.Conﬂict of interest
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